Research desk

A peptide news feed that treats sources with respect

We keep the stream editorial and source-first: regulatory updates, clinical developments, and research headlines, without mixing them into sales-y ticker copy.

Semaglutide 2.4 mg Reduces Cardiovascular Events in FLOW Trial

The FLOW trial demonstrated a 20% relative risk reduction in major adverse cardiovascular events among participants with type 2 diabetes and chronic kidney disease receiving weekly semaglutide 2.4 mg subcutaneous injections over a median follow-up of 3.4 years.

Mar 22, 2026Mar 22, 2026

semaglutideGLP-1weight-managementmetabolic